Advanced Life Sciences Holdings Inc. had Wednesday what Chairman and CEO Michael Flavin called "a great day," with the submission of its regulatory application for antibiotic cethromycin in community-acquired pneumonia (CAP), a potential $100 million-plus Asia-Pacific partnership deal with Wyeth and a couple of financing agreements to bolster its cash position. (BioWorld Today)